Top 21 Kesios Therapeutics investors
The most complete profiles first. Showing 21 of 21.
Eugene HillVerified
Venture Capital, Private Equity Firm, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 64 more
Verified email available
Jack KenneyVerified
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Contact details available
Ken HaasVerified
Venture Capital, Advisor, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Paul LaVioletteVerified
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 63 more
Verified email available
Tom FlynnVerified
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Verified email available
andrew sinclairVerified
Venture Capital, Private Equity Firm, Investor · United Kingdom
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Elizabeth Blake SchwertVerified
Venture Capital · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Verified email available
Mike RossVerified
Venture Capital · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Verified email available
Shelley ChuVerified
Venture Capital · United States
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Tim HainesVerified
Venture Capital · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Bali Muralidhar
Venture Capital, Private Equity Firm, Investor · United Kingdom
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more
Contact details available
Brian Gallagher, Jr.
Venture Capital, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more
Contact details available
Gregory Madden
Venture Capital, Private Equity Firm, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 63 more
Contact details available
Houman Ashrafian
Venture Capital, Investor · United Kingdom
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 64 more
Contact details available
Kurt von Emster
Venture Capital, Private Equity Firm, Investor · United States
Series BHealth CareWomen FoundedInvestment ManagementLife SciencePortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Michael Balmuth
Venture Capital, Private Equity Firm, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 64 more
Contact details available
Vin Miles
Venture Capital, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Brent Faduski
Venture Capital, Private Equity Firm · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Contact details available
Carl Culicchia
Venture Capital · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide and 62 more
Contact details available
John Heard
Venture Capital, Private Equity Firm · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Sarah Shackelton
Venture Capital · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
By investment stage
By location
Related industries
Most-backed portfolio companies
- TopiVert11
- NKT Therapeutics11
- CardioFocus11
- Cibiem, Inc.11
- Artios Pharma11
- Halscion, Inc.11
- CSA Medical11
- VHSquared11
- AllianceCare11
- Enara Bio11
- myOrthos11
Frequently asked questions
How many Kesios Therapeutics investors are on Angel Roster?
Angel Roster lists 21 Kesios Therapeutics investors. 9 of them (43%) include a verified email address.
What types of investors are they?
The most common investor types are Venture Capital Firms (21), Private Equity Firms (8) and Advisor Investors (1). An investor can have more than one type, for example an angel who is also a venture partner.
Which stages do Kesios Therapeutics investors invest in?
Among those that list a stage, the most common are Seed (7) and Series B (6).
Where are Kesios Therapeutics investors based?
Most are based in the United States (15) and the United Kingdom (6).
Which companies have Kesios Therapeutics investors backed?
The most-backed portfolio companies among them are TopiVert (11), NKT Therapeutics (11), CardioFocus (11), Cibiem, Inc. (11) and Artios Pharma (11).
How do I contact Kesios Therapeutics investors?
Create a free Angel Roster account to search and filter all 21, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.